These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 230784)

  • 21. In vitro and in vivo resistance of herpes simplex virus to 9-(2-hydroxyethoxymethyl)guanine (acycloguanosine).
    Smith KO; Kennell WL; Poirier RH; Lynd FT
    Antimicrob Agents Chemother; 1980 Feb; 17(2):144-50. PubMed ID: 6247967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of topical applications of phosphonoacetate on colonization of mouse trigeminal ganglia with herpes simplex virus type 1.
    Klein RJ; Friedman-Kien AE; Kaley L; Brady E
    Antimicrob Agents Chemother; 1984 Jul; 26(1):65-8. PubMed ID: 6089655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of oral treatment with acyclovir and bromovinyldeoxyuridine on the establishment of maintenance of latent herpes simplex virus infection in mice.
    Field HJ; De Clercq E
    J Gen Virol; 1981 Oct; 56(Pt 2):259-65. PubMed ID: 6273499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice.
    Cremer KJ; Mackett M; Wohlenberg C; Notkins AL; Moss B
    Science; 1985 May; 228(4700):737-40. PubMed ID: 2986288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Topical therapeutic efficacy of 9-(2-hydroxyethoxymethyl)guanine and 5-iodo-5'-amino-2',5'-dideoxyuridine on oral infection with herpes simplex virus in mice.
    Park NH; Pavan-Langston D; Hettinger ME; McLean SL; Albert DM; Lin TS; Prusoff WH
    J Infect Dis; 1980 May; 141(5):575-9. PubMed ID: 6966305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapeutic efficacy of E-5-(2-bromovinyl)-2'deoxyuridine for orofacial infection with herpes simplex virus type 1 in mice.
    Park NH; Pavan-Langston D; Boisjoly HM; De Clercq E
    J Infect Dis; 1982 Jun; 145(6):909-13. PubMed ID: 6979592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Latent herpes simplex virus infections in sensory ganglia of mice after topical treatment with adenine arabinoside and adenine arabinoside monophosphate.
    Klein RJ; Friedman-Kien AE
    Antimicrob Agents Chemother; 1977 Nov; 12(5):577-81. PubMed ID: 200172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of immune serum on the establishment of herpes simplex virus infection in trigeminal ganglia of hairless mice.
    Klein RJ
    J Gen Virol; 1980 Aug; 49(2):401-5. PubMed ID: 6255074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A herpes simplex virus type 1 mutant containing a nontransinducing Vmw65 protein establishes latent infection in vivo in the absence of viral replication and reactivates efficiently from explanted trigeminal ganglia.
    Steiner I; Spivack JG; Deshmane SL; Ace CI; Preston CM; Fraser NW
    J Virol; 1990 Apr; 64(4):1630-8. PubMed ID: 2157048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathogenesis of Herpes simplex virus infections in guinea pigs.
    Scriba M; Tatzber F
    Infect Immun; 1981 Dec; 34(3):655-61. PubMed ID: 6277787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute and latent infection of sensory ganglia with herpes simplex virus: immune control and virus reactivation.
    Openshaw H; Asher LV; Wohlenberg C; Sekizawa T; Notkins AL
    J Gen Virol; 1979 Jul; 44(1):205-15. PubMed ID: 227991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacies of gel formulations containing foscarnet, alone or combined with sodium lauryl sulfate, against establishment and reactivation of latent herpes simplex virus type 1.
    Piret J; Lamontagne J; Désormeaux A; Bergeron MG
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1030-6. PubMed ID: 11257012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection.
    Morrison LA; Knipe DM
    J Virol; 1994 Feb; 68(2):689-96. PubMed ID: 8289372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protection from oral herpes simplex virus infection by a nucleic acid-free virus vaccine.
    Kitces EN; Morahan PS; Tew JG; Murray BK
    Infect Immun; 1977 Jun; 16(3):955-60. PubMed ID: 197013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Latent herpes simplex virus in human trigeminal ganglia. Detection of an immediate early gene "anti-sense" transcript by in situ hybridization.
    Croen KD; Ostrove JM; Dragovic LJ; Smialek JE; Straus SE
    N Engl J Med; 1987 Dec; 317(23):1427-32. PubMed ID: 2825014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of herpes simplex virus infection and latency by prophylactic treatment with acyclovir in a weanling mouse model.
    Dobson AT; Little BB; Scott LL
    Am J Obstet Gynecol; 1998 Aug; 179(2):527-32. PubMed ID: 9731864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate.
    Coen DM; Kosz-Vnenchak M; Jacobson JG; Leib DA; Bogard CL; Schaffer PA; Tyler KL; Knipe DM
    Proc Natl Acad Sci U S A; 1989 Jun; 86(12):4736-40. PubMed ID: 2543985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ganglionic herpes simplex and systemic acyclovir.
    Pavan-Langston D; Park NH; Hettinger M
    Arch Ophthalmol; 1981 Aug; 99(8):1417-9. PubMed ID: 6266375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Latency of herpes simplex virus in absence of neutralizing antibody: model for reactivation.
    Sekizawa T; Openshaw H; Wohlenberg C; Notkins AL
    Science; 1980 Nov; 210(4473):1026-8. PubMed ID: 6254149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Route of infection, systemic host resistance, and integrity of ganglionic axons influence acute and latent herpes simplex virus infection of the superior cervical ganglion.
    Price RW; Schmitz J
    Infect Immun; 1979 Feb; 23(2):373-83. PubMed ID: 422245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.